Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adil I Daud

Showing results (61-70 of 85) with videos related to

Pageof 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignanciesJade Homsi, George R Simon, Chris R Garrett, et al.
Cancer Chemotherapy and Pharmacology|May 23, 2023
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanomaDrew W Rasco, Theresa Medina, Pippa Corrie, et al.
Molecular Cancer Research : MCR|March 18, 2022
Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor ImmunityMia Han, Bianca Nguyen, Jack Y Lee, et al.
Annals of Surgical Oncology|June 4, 2020
Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced MelanomaLauren S Levine, Kelly M Mahuron, Katy K Tsai, et al.
JCI Insight|July 21, 2017
Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapyKimberly Loo, Katy K Tsai, Kelly Mahuron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2019
Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell CarcinomaShailender Bhatia, Natalie V Longino, Natalie J Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2011
Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumorsAdil I Daud, Smitha S Krishnamurthi, Mansoor N Saleh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced MelanomaCaroline Robert, Matteo S Carlino, Catriona McNeil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumorsAdil I Daud, Michelle T Ashworth, Jonathan Strosberg, et al.
Cancer|August 18, 2016
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodiesAlain P Algazi, Katy K Tsai, Alexander N Shoushtari, et al.
Pageof 9

Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignanciesJade Homsi, George R Simon, Chris R Garrett, et al.
Cancer Chemotherapy and Pharmacology|May 23, 2023
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanomaDrew W Rasco, Theresa Medina, Pippa Corrie, et al.
Molecular Cancer Research : MCR|March 18, 2022
Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor ImmunityMia Han, Bianca Nguyen, Jack Y Lee, et al.
Annals of Surgical Oncology|June 4, 2020
Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced MelanomaLauren S Levine, Kelly M Mahuron, Katy K Tsai, et al.
JCI Insight|July 21, 2017
Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapyKimberly Loo, Katy K Tsai, Kelly Mahuron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2019
Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell CarcinomaShailender Bhatia, Natalie V Longino, Natalie J Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2011
Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumorsAdil I Daud, Smitha S Krishnamurthi, Mansoor N Saleh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced MelanomaCaroline Robert, Matteo S Carlino, Catriona McNeil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumorsAdil I Daud, Michelle T Ashworth, Jonathan Strosberg, et al.
Cancer|August 18, 2016
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodiesAlain P Algazi, Katy K Tsai, Alexander N Shoushtari, et al.
Pageof 9